bearish
Divi’s Laboratories - Miss in 2QFY23; Growth Factors to Face Softness over Medium Term
DIVI delivered an earnings miss in 2QFY23. Reduced traction in Custom Synthesis (CS), coupled with lower operating leverage resulted in an earnings decline for the first time
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 22-minute read)
Discussions
(Paid Plans Only)
Motilal Oswal
External broker reports(aggregated public sources)
Motilal Oswal Financial Services Limited
Price Chart(Sign Up to Access)
- Divi’s Laboratories - Miss in 2QFY23; Growth Factors to Face Softness over Medium Term12 Nov 2022
x